<DOC>
	<DOC>NCT02328482</DOC>
	<brief_summary>This will be a multi-center, randomized withdrawal, open-label, non-treatment concurrent control, parallel group study. Patients completing protocol BBCO-001 will be offered the opportunity to enter into this 12-month randomized withdrawal protocol.</brief_summary>
	<brief_title>Continuation Protocol to Protocol BBCO-001</brief_title>
	<detailed_description>This will be a multi-center, randomized withdrawal, open-label, non-treatment concurrent control, parallel group study. Patients completing protocol BBCO-001 will be offered the opportunity to enter into this 12-month randomized withdrawal protocol. Eligible patients will be randomized to one of the following treatment arms: - Treatment Arm 1: active treatment; continuation of 30 g IV Cabaletta once a week over an additional 52 weeks. - Treatment Arm 2: no-treatment concurrent control; discontinuation of IV Cabaletta and follow-up over 52 weeks. IV Cabaletta will be administered once a week to patients in Treatment Arm 1. All patients, regardless of treatment arm allocation, will undergo the same safety and efficacy assessments during the monthly site visits.</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Oculopharyngeal</mesh_term>
	<criteria>1. Adult men and women who participated and completed study BBCO001 2. Clinical and genetic diagnosis of OPMD 3. Able to provide written informed consent to participate in this study 4. Able to understand the requirements of the study and willing to comply with the requirements of the study 1. Pregnant or lactating 2. Currently receiving anticoagulant treatment (e.g., warfarin) 3. Any lifethreatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety 4. Known hypersensitivity to any ingredient in the Cabaletta IV infusion 5. Currently participating in another clinical trial (other than BBCO001) or have completed an interventional trial less than 30 days prior to the planned treatment start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>